|
|
 |
|
 |
|
|
|
|
Title:
|
Phase III Randomized Study of Four Weeks High Dose IFN-A2B in Stage T2B N0, T3A-BN0, T4A-B N0, and T1-4, N1A, 2A (microscopic) Melanoma - IRB# 03-24B
|
|
Treatments:
|
Interferon alpha-2b
|
|
Disease Site:
|
Melanoma
|
|
Disease SubSite:
|
Melanoma
|
|
Drug Provided:
|
-- none --
|
|
Comments:
|
|
|
Eligibility:
|
Pts. must have melanoma w/cutaneous origin; only pts. w/initial presentation of primary melanoma are eligible; pts. must not have clinically palpable lymphadenopathy; pts must meet one of the following criteria: 1)T3N0M0 - primary melanoma of 0-4 mm Breslow depth, clinically negative regional lymph nodes, pathologic status unknown 2) T3N0M0 - primary melanoma of 1.5-4 mm Breslow depth, histologically negative regional lymph nodes 3) T4N0M0 - primary melanoma > 4 mm Breslow depth 4) T1-4N1 - primary melanoma, one lymph node positive microscopically; pts. must complete all primary therapy (wide excision w/or w/o lymphadenectomy) and be randomized w/in 84 days of their wide excision.
|
|
Participating Sites:
|
Adventist Medical Center, Northwest Cancer Specialists, Providence Milwaukie Hospital, Providence Portland Medical Center, Providence St. Vincent Medical Center, Southwest Washington Medical Center
|
|
|
|
|
 |
|
 |
|
|
|